Connaught Labs' acellular pertusis vaccine
Executive Summary
PLA filed for bivalent acellular vaccine, firm said Jan. 11, for innoculation at 18 months of age. The vaccine, licensed for the U.S. from Biken, Japan, was studied in Japan and Sweden on children from three months to two years old and in U.S. trials in 18-month olds. Connaught said it is continuing to conduct studies in infants 2-6 months old, "but feels current results warrant" the PLA filing for 18-month olds.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.